(EXAS) EXACT Sciences - Ratings and Ratios
Colorectal, Breast, Colon, Hereditary, Tumor, Monitoring
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 50.3% |
| Value at Risk 5%th | 71.4% |
| Relative Tail Risk | -13.69% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.14 |
| Alpha | 50.94 |
| CAGR/Max DD | 0.51 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.506 |
| Beta | 0.810 |
| Beta Downside | 0.430 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.30% |
| Mean DD | 32.29% |
| Median DD | 36.65% |
Description: EXAS EXACT Sciences November 03, 2025
Exact Sciences Corp. (NASDAQ:EXAS) develops and commercializes non-invasive cancer screening and diagnostic tests, most notably Cologuard-a stool-based DNA and hemoglobin assay approved for colorectal cancer (CRC) detection and widely adopted in the U.S. screening pathway.
Beyond Cologuard, the firm offers a suite of genomic-based diagnostics, including the Oncotype DX series for breast, DCIS, and colon recurrence risk, the OncoExTra tumor-profiling panel for advanced cancers, and the RiskGuard hereditary cancer test. These products target high-margin, payer-reimbursed niches within oncology diagnostics.
Exact’s pipeline aims to expand into earlier-stage risk assessment, neoadjuvant treatment selection, and recurrence monitoring, leveraging partnerships with the Mayo Foundation and Johns Hopkins University to accelerate validation and market entry. The company’s pipeline breadth reduces reliance on any single product line, a key risk mitigant for investors.
Key metrics: FY 2023 revenue reached approximately $1.5 billion, driven by a ~15 % year-over-year increase in Cologuard sales, and the test now commands roughly 70 % of the U.S. stool-DNA market. The firm holds over $2 billion in cash and short-term investments, providing runway for pipeline development and potential acquisitions. Sector-wide, the aging U.S. population and expanding Medicare coverage for CRC screening underpin a multi-year growth tail for Exact’s core offerings.
For a deeper quantitative assessment, you may find the ValueRay platform’s EXAS valuation model a useful next step.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-986.6m TTM) > 0 and > 6% of Revenue (6% = 184.9m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 2.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.66% (prev 30.07%; Δ 2.59pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 386.8m > Net Income -986.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (189.3m) change vs 12m ago 2.42% (target <= -2.0% for YES) |
| Gross Margin 67.36% (prev 71.40%; Δ -4.03pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.73% (prev 39.89%; Δ 8.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -26.71 (EBITDA TTM -761.4m / Interest Expense TTM 36.7m) >= 6 (WARN >= 3) |
Altman Z'' -3.90
| (A) 0.17 = (Total Current Assets 1.59b - Total Current Liabilities 584.3m) / Total Assets 5.90b |
| (B) -0.78 = Retained Earnings (Balance) -4.62b / Total Assets 5.90b |
| (C) -0.15 = EBIT TTM -979.8m / Avg Total Assets 6.32b |
| (D) -1.36 = Book Value of Equity -4.61b / Total Liabilities 3.40b |
| Total Rating: -3.90 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 47.28
| 1. Piotroski 3.50pt |
| 2. FCF Yield 1.19% |
| 3. FCF Margin 8.02% |
| 4. Debt/Equity 1.01 |
| 5. Debt/Ebitda -2.29 |
| 6. ROIC - WACC (= -30.39)% |
| 7. RoE -40.39% |
| 8. Rev. Trend 98.08% |
| 9. EPS Trend 86.24% |
What is the price of EXAS shares?
Over the past week, the price has changed by +0.07%, over one month by +51.09%, over three months by +110.79% and over the past year by +64.05%.
Is EXAS a buy, sell or hold?
- Strong Buy: 17
- Buy: 6
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EXAS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 102 | 0.8% |
| Analysts Target Price | 102 | 0.8% |
| ValueRay Target Price | 104.3 | 3% |
EXAS Fundamental Data Overview November 29, 2025
P/E Forward = 185.1852
P/S = 6.2366
P/B = 7.6941
P/EG = -1.07
Beta = 1.472
Revenue TTM = 3.08b USD
EBIT TTM = -979.8m USD
EBITDA TTM = -761.4m USD
Long Term Debt = 2.33b USD (from longTermDebt, last quarter)
Short Term Debt = 37.8m USD (from shortTermDebt, last quarter)
Debt = 2.54b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.75b USD (from netDebt column, last quarter)
Enterprise Value = 20.75b USD (19.22b + Debt 2.54b - CCE 1.00b)
Interest Coverage Ratio = -26.71 (Ebit TTM -979.8m / Interest Expense TTM 36.7m)
FCF Yield = 1.19% (FCF TTM 247.1m / Enterprise Value 20.75b)
FCF Margin = 8.02% (FCF TTM 247.1m / Revenue TTM 3.08b)
Net Margin = -32.01% (Net Income TTM -986.6m / Revenue TTM 3.08b)
Gross Margin = 67.36% ((Revenue TTM 3.08b - Cost of Revenue TTM 1.01b) / Revenue TTM)
Gross Margin QoQ = 68.64% (prev 69.35%)
Tobins Q-Ratio = 3.52 (Enterprise Value 20.75b / Total Assets 5.90b)
Interest Expense / Debt = 0.39% (Interest Expense 9.79m / Debt 2.54b)
Taxrate = -10.35% (negative due to tax credits) (1.84m / -17.8m)
NOPAT = -1.08b (EBIT -979.8m * (1 - -10.35%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.72 (Total Current Assets 1.59b / Total Current Liabilities 584.3m)
Debt / Equity = 1.01 (Debt 2.54b / totalStockholderEquity, last quarter 2.50b)
Debt / EBITDA = -2.29 (negative EBITDA) (Net Debt 1.75b / EBITDA -761.4m)
Debt / FCF = 7.07 (Net Debt 1.75b / FCF TTM 247.1m)
Total Stockholder Equity = 2.44b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.72% (Net Income -986.6m / Total Assets 5.90b)
RoE = -40.39% (Net Income TTM -986.6m / Total Stockholder Equity 2.44b)
RoCE = -20.55% (EBIT -979.8m / Capital Employed (Equity 2.44b + L.T.Debt 2.33b))
RoIC = -22.39% (negative operating profit) (NOPAT -1.08b / Invested Capital 4.83b)
WACC = 8.00% (E(19.22b)/V(21.76b) * Re(9.0%) + D(2.54b)/V(21.76b) * Rd(0.39%) * (1-Tc(-0.10)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.19%
[DCF Debug] Terminal Value 66.25% ; FCFE base≈187.6m ; Y1≈123.2m ; Y5≈56.3m
Fair Price DCF = 5.00 (DCF Value 948.7m / Shares Outstanding 189.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 86.24 | EPS CAGR: 167.6% | SUE: 1.51 | # QB: 1
Revenue Correlation: 98.08 | Revenue CAGR: 16.89% | SUE: 3.21 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=+0.021 | Revisions Net=+0 | Analysts=7
EPS next Year (2026-12-31): EPS=1.12 | Chg30d=+0.023 | Revisions Net=+4 | Growth EPS=+230.6% | Growth Revenue=+13.6%
Additional Sources for EXAS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle